why choose us

First received: March 17, 2023

Clinical Trial: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced or Metastatic Solid Tumors

Study Type: INTERVENTIONAL


Official Title: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Brief Summary: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.

Read more